Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout


- Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)

- Comprehensive Part A data readout remains on track for the first quarter of 2027, supporting optimal dose selection and planned initiation of Part B

- Annamycin's differentiated cardiac safety profile further supported by peer-reviewed analysis of 90 patients across five clinical trials, with no evidence of clinical or subclinical cardiotoxicity at first interim analysis

- New preclinical findings suggest Annamycin may help turn immunologically “cold” pancreatic tumors “hot,” supporting potential combination treatment approaches

HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), reported on Friday the financial results for the third quarter ended September 30, 2026, and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin (also known as naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML).

Moleculin continues to advance its lead clinical program following completion of treatment for all 90 patients in Part A of the MIRACLE trial. The Company remains on track to report comprehensive Part A data in the first quarter of 2027. These data are expected to support selection of the optimal Annamycin dose for advancement into Part B, which is currently planned to begin in the first half of 2027.

"We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement. We are now focused on delivering the comprehensive dataset in the first quarter of 2027, which we expect will provide important insights into Annamycin's clinical activity, safety and optimal dose for advancement into Part B. We are also looking forward to releasing quantitative market research data soon, further supporting the commercial opportunity for Annamycin "

"What gives us confidence as we approach this readout is the totality of evidence generated to date," continued Mr. Klemp. "We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy. We believe Annamycin has the potential to address a meaningful treatment gap in AML, and the upcoming Part A results represent an important opportunity to further evaluate that potential. Our priority is clear: execute on the data readout, make informed development decisions and advance Annamycin toward its next critical milestones."

Recent Highlights

  • Completed treatment for all 90 patients in Part A of the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML. The Company remains on track for a comprehensive data readout in the first quarter of 2027. The full Part A dataset is expected to inform optimal dose selection for the planned initiation of Part B.
  • Published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine evaluating cardiac safety findings from 90 patients treated with Annamycin across five clinical trials in AML and metastatic soft tissue sarcoma. The analysis, independently evaluated by a cardio-oncology laboratory at Cleveland Clinic, found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.
  • Presented new preclinical data at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer indicating that Annamycin's antitumor activity in pancreatic cancer models is partially mediated by CD8+ T cell cytotoxicity. These findings suggest Annamycin may help expose immunologically “cold” tumors to immune attack, potentially supporting combination treatment approaches.
  • Announced acceptance of data from the MIRACLE trial for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. The presentation will highlight interim results from the pivotal Phase 2/3 trial in patients with relapsed or refractory AML.

Expected Milestones for the Annamycin Development Program

  • Q1 2027: MIRACLE – Comprehensive Part A data readout following completion of treatment for all 90 patients
  • 1H 2027: MIRACLE – Planned initiation of Part B following optimal dose selection
  • 1H 2027: Planned initiation of physician-sponsored clinical trial evaluating Annamycin for pancreatic cancer
  • 1H 2028: Planned initiation of third-line relapsed/refractory AML subject trial
  • 1H 2028: Planned initiation of pediatric AML clinical study
  • 2H 2028: Complete recruitment of Part B
  • 2H 2028: Primary efficacy data for MIRACLE 2nd line subjects
  • 2028-2029: Begin a rolling submission of a New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE

Additional Pipeline Programs

Moleculin continues to support development activities for its WP1066 program through investigator-sponsored research, including a physician-sponsored Phase 1B/2 clinical trial evaluating WP1066 in combination with radiation for the treatment of glioblastoma. These programs complement Moleculin's primary focus on advancing Annamycin.

Third Quarter 2026 Financial Results

Research and development expenses were approximately $4.5 million for the three months ended September 30, 2026, compared to approximately $3.7 million for the same period in 2025. The increase was primarily attributable to activities related to the MIRACLE clinical trial.

General and administrative expenses were approximately $2.1 million for the three months ended September 30, 2026, compared to approximately $2.1 million for the same period in 2025.

Net loss for the third quarter of 2026 was approximately $6.5 million, compared to approximately $25.4 million for the same period in 2025. The decrease in net loss was primarily attributable to the absence of the approximately $20.6 million non-cash loss on the issuance of warrant liabilities recorded in the prior-year period.

For the nine months ended September 30, 2026, research and development expenses were approximately $15.3 million, compared to approximately $10.8 million for the same period in 2025. The increase was primarily related to the MIRACLE clinical trial, additional nonclinical studies and other research costs. General and administrative expenses were approximately $6.7 million for the nine months ended September 30, 2026, compared to approximately $6.7 million for the same period in 2025.

As of September 30, 2026, Moleculin had cash and cash equivalents of approximately $7.3 million, compared to approximately $8.9 million as of December 31, 2025. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $21.7 million.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation: the potential efficacy and safety of Annamycin; the potential for Annamycin to be used in combination with immune checkpoint inhibitors or in indications other than AML; the timing and results of the comprehensive Part A data readout of the MB-108 trial; the planned initiation of Part B of the MIRACLE trial in the first half of 2027 and the expected timeline for completing Part B recruitment; the potential for the MB-108 trial to support a New Drug Application submission, including the anticipated rolling NDA submission during 2028-2029; the planned initiation of a third-line relapsed/refractory AML clinical study and a pediatric AML clinical study, each anticipated in the first half of 2028; the Company’s plans to sponsor an investigator-initiated clinical trial of Annamycin in pancreatic cancer; and the Company’s ability to secure additional financing to conduct its clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the completion of the clinical trials described in this press release assumes the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Moleculin Biotech, Inc.
Unaudited Condensed Consolidated Balance Sheets
(in thousands) September 30, 2026  December 31, 2025 
Current assets:        
Cash and cash equivalents $7,287  $8,878 
Prepaid expenses and other current assets  1,124   808 
Total current assets  8,411   9,686 
Intangible assets  11,148   11,148 
Other non-current assets  900   900 
Operating lease right-of-use asset  223   314 
Furniture and equipment, net  54   78 
Total assets $20,736  $22,126 
         
Current liabilities:        
Accounts payable and other current liabilities $6,135  $6,854 
Total current liabilities  6,135   6,854 
Operating lease liability - long-term, net of current portion  107   222 
Warrant liability - long term  5   44 
Total liabilities  6,247   7,120 
Total stockholders' equity  14,489   15,006 
Total liabilities and stockholders' equity $20,736  $22,126 


Unaudited Condensed Consolidated Statements of Operations
  Three Months Ended September 30,  Nine Months Ended September 30, 
(in thousands, except share and per share amounts)  2026   2025   2026   2025 
Revenues $-  $-  $-  $- 
Operating expenses:                
Research and development  4,488   3,738   15,317   10,774 
General and administrative  2,114   2,147   6,705   6,715 
Depreciation and amortization  8   21   24   81 
Total operating expenses  6,610   5,906   22,046   17,570 
Loss from operations  (6,610)  (5,906)  (22,046)  (17,570)
Other income (loss):                
Gain from change in fair value of warrant liability  35   1,591   10,798   1,031 
Transaction costs allocated to equity and liability warrant issuances  (12)  (530)  (707)  (1,737)
Loss on issuance of warrant liabilities  -   (20,609)  (15,158)  (30,962)
Other income, net  36   16   125   30 
Interest income, net  58   39   15   96 
Net loss $(6,493) $(25,399) $(26,973) $(49,112)
Warrant deemed dividends  (773)  -   (2,867)  - 
Net loss available to common stockholders $(7,266) $(25,399) $(29,840) $(49,112)
Net loss per common share - basic and diluted $(9.59) $(340.43) $(71.38) $(1,179.03)
Weighted average common shares outstanding - basic and diluted  757,858   74,609   418,060   41,655 



GlobeNewswire